Phase 2 OCD Trial, Recruiting NCT04882839 Sponsor: Beersheva Mental Health Center Condition: OCD
Back to Ocd

Phase 2 OCD Trial, Recruiting

NCT04882839
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been officially diagnosed with OCD (Obsessive-Compulsive Disorder) by a trained mental health professional.
  • Your OCD symptoms score 16 or higher on a standard OCD rating scale (called the Y-BOCS), indicating significant symptoms.
  • Your OCD has not improved enough after trying at least one standard medication or therapy treatment.
  • You are between 18 and 65 years old.
  • You have stopped taking certain antidepressants (SSRIs) for a specific washout period before joining (confirm exact timing with trial site).
  • You agree not to start any new therapy or psychiatric medication during the study without checking with the study team first.
  • You are willing to avoid all psychiatric medications and recreational drugs throughout the study.
  • If you could become pregnant, you have a negative pregnancy test at the start and before each study session, and you agree to use reliable contraception.
  • You are willing to allow the researchers to speak with your doctors or therapist to verify your medical and medication history if needed.
  • You can provide a contact person (such as a family member or close friend) who can be reached by the research team in an emergency.
  • You are committed to attending all medication sessions, therapy sessions, and follow-up appointments for the full study.

Who may not be able to join:

  • You or a close family member have a history of schizophrenia, bipolar disorder, delusional disorder, paranoid disorder, or schizoaffective disorder.
  • You have had a substance abuse problem in the past 12 months.
  • You have an unstable neurological or medical condition.
  • You currently have thoughts of suicide or have attempted suicide in the past 12 months.
  • You have a history of violence, self-harm, or harming others.
  • You have any unstable health condition that could make the study procedures unsafe.
  • You have a positive pregnancy test at the time of screening.
  • You have used any psychedelic drugs in the past 12 months.
  • You are not able to understand and sign a consent form agreeing to take part.
  • You experience an unexpected or unusual reaction to any part of the study while it is ongoing.
  • You decide you would like to stop participating once the study has begun.
  • You have a positive pregnancy test at any point before the final psychedelic session.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Oded Arbel, MD, Beersheva Mental Health Center

Phone: +972506576691

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Beersheva Mental Health Center
Registry
ClinicalTrials.gov
Start date
25 November 2024
Est. completion
1 June 2026

Where this trial is recruiting

🇮🇱 Israel

Primary endpoints

Yale-Brown Obsessive-Compulsive Scale (Y-BOCS ) change from baseline; Obsessive-Compulsive Inventory-Revised (OCI-R) change from baseline; Obsessional Beliefs Questionnaire (OBQ-20) change from baseline; Beck Depression Inventory -II (BDI-II) change from baseline; Beck Anxiety Inventory (BAI) change from baseline; Mini International Neuropsychiatric Interview (M.I.N.I.) change from baseline

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov